Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections
about
Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-AnalysisQuestioning the accuracy of trough concentrations as surrogates for area under the curve in determining vancomycin safety.Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.Intrathoracic irrigation with arbekacin for methicillin-resistant Staphylococcus aureus empyema following lung resection.New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients.Effects of aggregate and individual antibiotic exposure on vancomycin MICs for Staphylococcus aureus isolates recovered from pediatric patientsThe impact of serum vancomycin levels and minimum inhibitory concentrations of methicillin-resistant Staphylococcus aureus on mortality in patients with nosocomial pneumonia.Is therapeutic drug monitoring of teicoplanin useful?Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.Vancomycin serum trough concentration vs. clinical outcome in patients with gram-positive infection: a retrospective analysis.Comment on "Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction".Review on Usage of Vancomycin in Livestock and Humans: Maintaining Its Efficacy, Prevention of Resistance and Alternative Therapy.Interventions Targeting the Prescribing and Monitoring of Vancomycin for Hospitalized Patients: A Systematic Review Protocol.Vancomycin MICs of the resistant mutants of S. aureus ATCC43300 vary based on the susceptibility test methods used.Pharmacist-led implementation of a vancomycin guideline across medical and surgical units: impact on clinical behavior and therapeutic drug monitoring outcomes.Interventions targeting the prescribing and monitoring of vancomycin for hospitalized patients: a systematic review with meta-analysis
P2860
Q26770913-058C2CD5-D37B-4579-9608-471C34A32C24Q33949459-50DB51D6-04FD-4A99-8B18-AA83CDC161DCQ35004943-2464B153-764E-4045-B12B-EABDDA42CD79Q36175569-E462D47A-3242-40F5-8303-0DF0672FC676Q37120168-8E71F2D7-0EBB-4817-BC14-B55C71AFBC33Q37125081-D27AB198-33F3-403B-8568-6AE5F661C9CAQ37366784-B99F74DB-208A-4A3E-A562-8EEBFF72AE82Q37673485-55FCDA99-8EAF-4DCB-910A-0AD985A6C57AQ38258649-0B38FBCE-DA45-467C-92C8-08DC36DD3D68Q38907793-947FD1F4-1E8B-4E9A-99F1-00AD52572501Q40321062-FD21074A-AB24-49D9-9FC9-C70F9209E730Q40526316-E738BEB9-F65E-4781-B8F6-ED20403E0C01Q41208737-77C7B076-2F1D-4700-A05C-62094BFA2B9BQ43378543-1759AEC5-FF3E-4677-9B24-1163B7AD02BCQ47142517-AAACD4F5-7CA3-41E4-9AD5-9AE8A888849CQ48575528-18482C74-9728-4190-8E60-961B7D9B0C4DQ49392078-1FFA7DD0-3569-49E6-B8A7-EC53F80A0D6FQ59125936-E587B290-0A69-4A33-AADD-310E128966CE
P2860
Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Use of vancomycin pharmacokine ...... e treatment of MRSA infections
@ast
Use of vancomycin pharmacokine ...... e treatment of MRSA infections
@en
type
label
Use of vancomycin pharmacokine ...... e treatment of MRSA infections
@ast
Use of vancomycin pharmacokine ...... e treatment of MRSA infections
@en
prefLabel
Use of vancomycin pharmacokine ...... e treatment of MRSA infections
@ast
Use of vancomycin pharmacokine ...... e treatment of MRSA infections
@en
P2093
P2860
P356
P1476
Use of vancomycin pharmacokine ...... e treatment of MRSA infections
@en
P2093
Christopher Giuliano
Krystal K Haase
Ronald Hall
P2860
P304
P356
10.1586/ERI.09.123
P577
2010-01-01T00:00:00Z